Petros jumps on positive OTC label study data for erectile dysfunction drug

Petros Pharmaceuticals

19/04/2022 16:02

** Shares of men's health therapeutics company  PTPI.O 
surge 40% to $1.57; set for their best day since Dec 2021
    ** Petros Pharmaceuticals reports positive results from a
over-the-counter (OTC) label comprehension study for its
erectile dysfunction drug Stendra, which is currently available
only through prescription  urn:newsml:reuters.com:*:nGNX99CKXx
    ** In the study, 453 subjects, including low health literacy
individuals, reviewed a draft OTC label, and more than 95% of
participants provided correct or acceptable responses to
questions related to the label
    ** PTPI says these results suggest that the draft drug facts
labeling language as written may be appropriate for submission
to the FDA for review for OTC labeling
    ** About 37.1 mln shares of the New York-based company have
traded so far, 89 times their 30-DMA volume of 422,561 shares
    ** The shares are now down 53% for the year

 (Reporting by Devik Jain in Bengaluru)
 ((Devik.Jain@thomsonreuters.com; within U.S. +1 646 223 8780;
outside U.S. +91 80 6182 2062; ;))